Oligonucleotide‐Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy
Immunity, Inflammation and Disease · 2025-05 · 13 (5)
DOI: 10.1002/iid3.70200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 05.05.2025. Verfasst von Hanfu Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Immunity & Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Macrophages, Immunotherapy, Oligonucleotides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study is funded by the National Natural Science Foundation of China (Grant No. 82472826)..
Abstract (Originalsprache)
Background
Recent advances in immunotherapy have spotlighted macrophages as central mediators of disease treatment. Their polarization into pro‑inflammatory (M1) or anti‑inflammatory (M2) states critically influences outcomes in cancer, autoimmunity, and chronic inflammation. Oligonucleotides have emerged as highly specific, scalable, and cost‑effective agents for reprogramming macrophage phenotypes.
Objective
To review oligonucleotide strategies—including ASOs, siRNAs, miRNA mimics/inhibitors, and aptamers—for directing macrophage polarization and their therapeutic implications. Review Scope We examine key signaling pathways governing M1/M2 phenotypes, describe four classes of oligonucleotides and their mechanisms, and highlight representative preclinical and clinical applications. Key Insights Agents such as AZD9150, MRX34, and AS1411 demonstrate macrophage reprogramming in cancer, inflammation, and infection models. Advances in ligand‑conjugated nanoparticles and chemical modifications improve delivery and stability, yet immunogenicity, off‑target effects, and formulation challenges remain significant barriers. Future Perspectives Optimizing delivery platforms, enhancing molecular stability, and rigorous safety profiling are critical. Integration with emerging modalities—such as engineered CAR‑macrophages—will enable precise, disease‑specific interventions, and advance oligonucleotide‑guided macrophage modulation toward clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Immunity & Inflammation, Institute of Immunology, Naval Medical University, Shanghai, China.
- School of Molecular Sciences, University of Western Australia, Crawley, WA, Australia.
ORCID-Profile: Hanfu Zhang, Cheng Qian
Förderung
- This study is funded by the National Natural Science Foundation of China (Grant No. 82472826).
Zitieren
APA
Zhang, H., Yu, Y., & Qian, C. (2025). Oligonucleotide‐Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy. Immunity, Inflammation and Disease, 13(5). https://doi.org/10.1002/iid3.70200
Vancouver
Zhang H, Yu Y, Qian C. Oligonucleotide‐Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy. Immunity, Inflammation and Disease. 2025;13(5). doi:10.1002/iid3.70200
BibTeX
@article{Zhang2025,
author = {Zhang, Hanfu and Yu, Yizhi and Qian, Cheng},
title = {Oligonucleotide‐Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy},
journal = {Immunity, Inflammation and Disease},
year = {2025},
volume = {13},
number = {5},
doi = {10.1002/iid3.70200}
}
EUVIMED